Pipeline of first-in-class ADCs
We are progressing a pipeline of proprietary differentiated ADCs based on our novel N-myristoyltransferase inhibitor (NMTi) payload chemistry platform to address serious unmet needs in oncology.
Based on compelling preclinical efficacy and safety data across multiple solid tumour-associated antigens and cancer cell types we are prioritising two proprietary, differentiated NMTi-ADCs that target the cancer associated antigens:
- B7-H3
- HER2
Developing NMTis as a new therapeutic payload class
Currently over 90% of the clinical ADC pipeline is based on three mechanisms of action: tubulin binders, topoisomerase inhibitors, and DNA binders. There is a need to diversify the ADC pipeline with a novel, orthogonal and differentiated mechanism of action.
Our potent and selective NMTis show efficacy across multiple cancer cell lines, as well as exhibiting complete tumour regression in in vivo models of solid cancers, including those poorly responsive to well-known payload classes.
